
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For the Month of August, 2014

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant's name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_____.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: August 19, 2014

By: /s/ "Gregory Chow"

Gregory Chow

Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

99.1 Report of Voting Results - Lorus Therapeutics Inc.



Report of Voting Results
Lorus Therapeutics Inc.

In accordance with Section 11.3 of National Instrument 51-102, the following describes the matters voted upon and the outcome of the votes at the annual and special meeting of shareholders of Lorus Therapeutics Inc. (the "Corporation") held on August 19, 2014 in Toronto, Ontario.

1. By a resolution passed by a majority of the votes cast by a show of hands, each of the following directors were elected to hold office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Dr. Denis Burger	69,661,597	92.25	5,852,096	7.75
Dr. William G. Rice	74,411,586	98.54	1,102,107	1.46
Dr. Bradley Thompson	69,662,279	92.25	5,851,414	7.75
Dr. Brian Underdown	69,256,238	91.71	6,257,455	8.29
Dr. Mark D. Vincent	68,661,424	90.93	6,852,269	9.07
Warren Whitehead	69,662,623	92.25	5,851,070	7.75

2. By a resolution passed by a majority of the votes cast by a show of hands (of which approximately 99.33% of the votes represented by proxy voted in favour and approximately 0.67% of the votes represented by proxy withheld from voting), KPMG LLP was re-appointed as auditor of the Corporation to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration.
3. By a majority of the votes cast by a show of hands (of which approximately 98.99% of the votes represented by proxy voted in favour and approximately 1.01% of the votes represented by proxy voted against), the resolutions contained on page 10 of the Corporation's Management Information Circular (a copy of which is attached hereto) were passed relating to the proposed Change of Name.
4. By a majority of the votes cast by a show of hands (of which approximately 98.92% of the votes represented by proxy voted in favour and approximately 1.08% of the votes represented by proxy voted against), the resolutions contained on page 12 of the Corporation's Management Information Circular (a copy of which is attached hereto) were passed relating to the proposed Share Consolidation.

In total, 77,658,858 shares of the Corporation (representing approximately 55.74% of the issued and outstanding shares) were represented in person or by proxy at the meeting.

Yours very truly,

/s/ Gregory Chow

Gregory Chow
 Chief Financial Officer

**EXTRACT FROM PAGE 10 OF THE
CORPORATIONS' MANAGEMENT INFORMATION CIRCULAR**

Change of Name:

BE IT RESOLVED AS A SPECIAL RESOLUTION OF THE SHAREHOLDERS THAT :

1. The Corporation is hereby authorized under section 173 of the *Canada Business Corporations Act* (the "CBCA") to amend its articles to change the name of the Corporation from "Lorus Therapeutics Inc." to "Aptose Biosciences Inc." or such other name as may be approved by the directors of the Corporation and is acceptable to the Director under the CBCA and the TSX;
2. The board of directors of the Corporation (the "Board") be and it is hereby authorized to revoke, without further approval of the Shareholders, this special resolution at any time prior to the completion thereof, notwithstanding the approval by the Shareholders of same, if determined, in the Board's sole discretion to be in the best interest of the Corporation; and
3. Any director or officer of the Corporation is authorized and directed to execute and deliver for and in the name of and on behalf of the Corporation, under its corporate seal or otherwise, all such certificates, instruments, agreements, notices and other documents and to do such other acts and things as, in the opinion of such persons, may be necessary or desirable in connection with the proposed Name Change, including but not limited to, the filing of articles of amendment under the CBCA, with the performance of the Corporation of its obligations in connection therewith, and to give effect to the foregoing and facilitate the implementation of the foregoing resolutions.

**EXTRACT FROM PAGE 12 OF THE
CORPORATIONS' MANAGEMENT INFORMATION CIRCULAR**

Share Consolidation:

BE IT RESOLVED AS A SPECIAL RESOLUTION OF THE SHAREHOLDERS THAT :

1. Pursuant to the *Canada Business Corporations Act* (the "CBCA"), the articles of Lorus Therapeutics Inc. (the "Corporation") be amended to consolidate all of the issued and outstanding common shares of the Corporation (the "Shares") on the basis of a ratio of one (1) post-consolidation Share for each five (5) to fifteen (15) outstanding pre-consolidation Shares, with such ratio to be determined by the board of directors of the Corporation (the "Board") in its sole discretion. Any resulting fractional Shares shall be either rounded up or down to the nearest whole Share;
2. The Board be and it is hereby authorized to revoke, without further approval of the Shareholders, this special resolution at any time prior to the completion thereof, notwithstanding the approval by the Shareholders of same, if determined, in the Board's sole discretion to be in the best interest of the Corporation; and
3. Any director or officer of the Corporation is authorized and directed to execute and deliver for and in the name of and on behalf of the Corporation, under its corporate seal or otherwise, all such certificates, instruments, agreements, notices and other documents and to do such other acts and things as, in the opinion of such persons, may be necessary or desirable in connection with the proposed Share Consolidation, including but not limited to, the filing of articles of amendment under the CBCA, with the performance of the Corporation of its obligations in connection therewith, and to give effect to the foregoing and facilitate the implementation of the foregoing resolutions.